Follow
T cell infiltration tumor
T cells are a type of immune cell involved in identifying and killing cancer cells. T cells that infiltrate tumors, known as tumor infiltrating T cells (TILs), are a positive prognostic factor for cancer patients. Cellular therapies remove TILs from a patient, expand them in a laboratory, and administer them back to the patient.
-
MAY 19, 2020 | 11:15 AM
Background: Growing evidence supports the critical role of preexisting immune response in triple negative breast cancer (TNBC). However, there are limitations with current evaluation approac...APR 21, 2020 | 1:30 PM
Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for 10-20% of all breast cancer cases diagnosed annually in the U.S.1. Despite its prevalence, TNBC remains resist...Speaker: Dina Finan, PhD , Stephen Williams, PhDPresented at: Genetics Week Virtual Event Series 2020
APR 14, 2020 | 9:00 AM
DATE: April 14, 2020 TIME: 9:00am PDT, 12:00pm EDT Besides being Gibco Cell Culture Heroes, what do Vivek, Sandra, Daisy, Ameet and Kristine all have in common? They are all stuck at home fo...Speaker: Kristine Wadosky, PhD , Ameet Chimote, PhD , Elizabeth Delery, PhD , Daisy Shu, B.Optom, PhD , Vivek Kamat, PhD , Sandra Hammer, PhDSponsored By: Thermo Fisher Scientific/GibcoOCT 10, 2019 | 10:30 AM
Osteosarcoma (OS) is the most common bone tumor in pediatric and adolescent/young adult patients. Over the past three decades, significant improvements in the survival rates or therapeutic ap...Speaker: Troy McEachron, PhDPresented at: Cancer Research & Oncology Week Virtual Event Series 2019
Sponsored By: NanoString TechnologiesFEB 27, 2019 | 10:30 AM
Advanced Cell Diagnostics’ RNAscope products and assay services are utilized widely for tissue-based gene expression analysis in early target validation, preclinical animal efficacy and...Speaker: Christopher Bunker, PhDOCT 10, 2018 | 12:00 PM
To date the anatomic extent of tumor (TNM-classification) has been by far the most important factors to predict the prognosis of cancer patients. However, this classification provides limited...Speaker: Jerome Galon, PhDSEP 20, 2018 | 9:00 AM
DATE: September 20 2018TIME: 09:00am PDT, 12:00pm EDT Harnessing the immune system has emerged as a powerful therapeutic strategy in oncology. However, the limited...JAN 25, 2018 | 8:00 AM
DATE: January 25, 2018TIME: 8:00AM PST, 10:00AM CSTProstate cancer (PCa) is the most common noncutaneous malignancy in men in the US. A significant fraction of advanced PCa treate...NOV 15, 2017 | 10:00 AM
DATE: November 15, 2017TIME: 10:00AM PTInteractions between tumor and immune cells in the tumor microenvironment (TME) play a key role in tumor progression and treatment response, with...NOV 14, 2017 | 10:00 AM
DATE: November 14, 2017TIME: 10:00am PST, 1:00pm ESTSuccessful tumor outgrowth requires the coordination of a variety of cell intrinsic and cell extrinsic signaling events. These events...Speaker: Jeffrey Rodvold, PhDSponsored By: Thermo Fisher Scientific/Gibco, Thermo Fisher Scientific/GibcoOCT 12, 2017 | 6:00 AM
We developed two computational methods, CARE and TIDE, to predict response and resistance to targeted therapies and immunotherapies. CARE infers gene signatures of targeted therapy response b...Speaker: Xiaole Shirley Liu, PhDOCT 06, 2016 | 9:00 AM
The immune system is capable of recognizing tumors and eliminates many early malignant cells. However, tumors evolve to evade immune attack, and the tumor microenvironment is immunosuppressiv...Speaker: Gordon Freeman, PhDOCT 30, 2014 | 12:00 PM
It has become widely accepted that the presence of intraepithelial CD8+ T cell correlate with improved patient survival. In contrast, tumors largely devoid of immune infiltrations or infiltra...Speaker: Julian J. Lum, PhD
MAY 19, 2020 | 11:15 AM
Background: Growing evidence supports the critical role of preexisting immune response in triple negative breast cancer (TNBC). However, there are limitations with current evaluation approac...
APR 21, 2020 | 1:30 PM
Triple-negative breast cancer (TNBC) is an aggressive disease that accounts for 10-20% of all breast cancer cases diagnosed annually in the U.S.1. Despite its prevalence, TNBC remains resist...
Speaker:
Dina Finan, PhD
, Stephen Williams, PhD
Presented at: Genetics Week Virtual Event Series 2020
APR 14, 2020 | 9:00 AM
DATE: April 14, 2020 TIME: 9:00am PDT, 12:00pm EDT Besides being Gibco Cell Culture Heroes, what do Vivek, Sandra, Daisy, Ameet and Kristine all have in common? They are all stuck at home fo...
Speaker:
Kristine Wadosky, PhD
, Ameet Chimote, PhD
, Elizabeth Delery, PhD
, Daisy Shu, B.Optom, PhD
, Vivek Kamat, PhD
, Sandra Hammer, PhD
Sponsored By: Thermo Fisher Scientific/Gibco
OCT 10, 2019 | 10:30 AM
Osteosarcoma (OS) is the most common bone tumor in pediatric and adolescent/young adult patients. Over the past three decades, significant improvements in the survival rates or therapeutic ap...
Speaker:
Troy McEachron, PhD
Presented at: Cancer Research & Oncology Week Virtual Event Series 2019
Sponsored By: NanoString Technologies
Sponsored By: NanoString Technologies
FEB 27, 2019 | 10:30 AM
Advanced Cell Diagnostics’ RNAscope products and assay services are utilized widely for tissue-based gene expression analysis in early target validation, preclinical animal efficacy and...
Speaker:
Christopher Bunker, PhD
OCT 10, 2018 | 12:00 PM
To date the anatomic extent of tumor (TNM-classification) has been by far the most important factors to predict the prognosis of cancer patients. However, this classification provides limited...
Speaker:
Jerome Galon, PhD
SEP 20, 2018 | 9:00 AM
DATE: September 20 2018TIME: 09:00am PDT, 12:00pm EDT Harnessing the immune system has emerged as a powerful therapeutic strategy in oncology. However, the limited...
JAN 25, 2018 | 8:00 AM
DATE: January 25, 2018TIME: 8:00AM PST, 10:00AM CSTProstate cancer (PCa) is the most common noncutaneous malignancy in men in the US. A significant fraction of advanced PCa treate...
NOV 15, 2017 | 10:00 AM
DATE: November 15, 2017TIME: 10:00AM PTInteractions between tumor and immune cells in the tumor microenvironment (TME) play a key role in tumor progression and treatment response, with...
NOV 14, 2017 | 10:00 AM
DATE: November 14, 2017TIME: 10:00am PST, 1:00pm ESTSuccessful tumor outgrowth requires the coordination of a variety of cell intrinsic and cell extrinsic signaling events. These events...
Speaker:
Jeffrey Rodvold, PhD
Sponsored By: Thermo Fisher Scientific/Gibco,
Thermo Fisher Scientific/Gibco
OCT 12, 2017 | 6:00 AM
We developed two computational methods, CARE and TIDE, to predict response and resistance to targeted therapies and immunotherapies. CARE infers gene signatures of targeted therapy response b...
Speaker:
Xiaole Shirley Liu, PhD
OCT 06, 2016 | 9:00 AM
The immune system is capable of recognizing tumors and eliminates many early malignant cells. However, tumors evolve to evade immune attack, and the tumor microenvironment is immunosuppressiv...
Speaker:
Gordon Freeman, PhD
OCT 30, 2014 | 12:00 PM
It has become widely accepted that the presence of intraepithelial CD8+ T cell correlate with improved patient survival. In contrast, tumors largely devoid of immune infiltrations or infiltra...
Speaker:
Julian J. Lum, PhD